AUS
NZ
UK
CA
USA
IND
Healthcare
Talkiatry is enhancing its postpartum depression care services to better address maternal mental health needs
October 08, 2024 05:57 AM PDT| By Team Kalkine MediaHighlights:,Talkiatry has introduced a new initiative to support women experiencing postpartum depression (PPD) through virtual appointments with board-certified psychiatrists.,The company has launched educational resources to help identify PPD sympt...
Bio-Path Holdings has commenced the development of a therapeutic program to address obesity
October 08, 2024 05:55 AM PDT| By Team Kalkine MediaHighlights:,Bio-Path Holdings has launched a new therapeutic program for BP1001-A, targeting obesity and related metabolic diseases, marking a novel application of their DNAbilize® technology.,Enrollment is complete for the third dosing cohort in the...
Is This Company’s Financial Strategy Worth Your Watch In 2024?
October 07, 2024 01:42 PM PDT| By Team Kalkine MediaHighlights,CareCloud’s current debt load has significantly decreased compared to last year, showing efforts to reduce financial obligations.,The company’s cash reserves offset much of the debt, leaving a manageable net debt level for operations.,Whil...
Phio presents data that underscores INTASYL's significance in immune cell-mediated cancer cell destruction
October 07, 2024 06:20 AM PDT| By Team Kalkine MediaHighlights:,Phio Pharmaceuticals Corp. has unveiled data from its proprietary INTASYL platform, which effectively silences mRNA to enhance immune responses against cancer.,Key INTASYL compounds include PH-762, PH-894, PH-804, and PH-905, each targeti...
Phase 3 SAPPHIRE study results reveal that Apitegromab meets its primary endpoint in treating patients with SMA, as reported by Scholar Rock
October 07, 2024 05:53 AM PDT| By Team Kalkine MediaHighlights:,Scholar Rock announced positive topline results from the Phase 3 SAPPHIRE clinical trial for apitegromab, showing a statistically significant improvement in motor function in patients with Spinal Muscular Atrophy (SMA).,The trial met its...
Philips and Siloam Hospitals Join Forces to Advance AI in Indonesian Healthcare
October 07, 2024 05:01 AM PDT| By Team Kalkine MediaHighlights,Philips and Siloam Hospitals partner to enhance AI capabilities in Indonesian healthcare.,Collaboration aims to improve clinical outcomes and support digital transformation.,Focus on local expertise and global knowledge sharing to build a...
GE HealthCare Completes Phase I Development of Innovative Manganese-Based MRI Contrast Agent
October 07, 2024 04:56 AM PDT| By Team Kalkine MediaHighlights,GE HealthCare completes Phase I trial for innovative manganese-based MRI contrast agent.,New contrast agent shows promising safety profile, potentially reducing environmental impact.,GE HealthCare celebrates 150 years of innovation in Norw...
Supply bottlenecks lead to a downgrade for Novo Nordisk
October 07, 2024 04:13 AM PDT| By Team Kalkine MediaHighlights:,Jefferies downgrades Novo Nordisk to "underperform," citing concerns over the supply of its weight-loss drug, Wegovy, particularly in the United States.,Recent data indicates a significant decline in Wegovy prescriptions, especially for t...
A stake worth $1 billion in Pfizer is secured by activist interest Starboard Value
October 07, 2024 03:28 AM PDT| By Team Kalkine MediaHighlights:,Activist firm Starboard Value has acquired a substantial stake in Pfizer Inc and is advocating for strategic changes within the pharmaceutical company.,Starboard has engaged with former Pfizer executives to bolster its initiatives aimed a...
Rise in Futura Medical shares is attributed to receipt of $5 million US milestone payment
October 07, 2024 03:23 AM PDT| By Team Kalkine MediaHighlights:,Futura Medical PLC secures a significant milestone payment following the US launch of its erectile dysfunction gel, Eroxon.,Eroxon becomes the first over-the-counter treatment for erectile dysfunction available in the US market.,Stifel pr...
Penumbra's Path: Navigating Growth Through Capital Allocation
October 06, 2024 12:42 PM PDT| By Team Kalkine MediaHeadlines,Identifying Key Trends for Long-Term Value Growth,Analyzing Penumbra's Return on Capital Employed,Assessing Investment Strategies for Future Success,Penumbra,(NYSE:PEN),has been attracting attention in the stock market, raising questions ab...
Significant Insider Investments Highlight Confidence in Biohaven's Growth
October 06, 2024 12:13 PM PDT| By Team Kalkine MediaHeadlines,Insider Buying Indicates Confidence,Notable Transactions Over the Past Year,High Insider Ownership Reflects Alignment with Shareholders,Vladimir Coric, the Chairman and CEO of Biohaven Ltd.,(NYSE:BHVN),recently acquired a significant amount...
Molecular Partners Set to Present Posters at the 2024 SITC Annual Meeting
October 04, 2024 06:12 AM PDT| By Team Kalkine MediaHighlights:,Molecular Partners AG will present proof-of-concept data for its novel CD3 Switch-DARPin at the 2024 SITC Annual Meeting.,The company will also showcase additional analyses from the Phase 1 study of MP0317, focusing on advanced solid tumo...
Summit Therapeutics Completes Enrollment in Its Phase III HARMONi Trial
October 04, 2024 06:09 AM PDT| By Team Kalkine MediaHighlights:,Summit Therapeutics has completed enrollment for the HARMONi Phase III clinical trial, evaluating ivonescimab in combination with platinum-doublet chemotherapy for EGFR-mutated non-small cell lung cancer (NSCLC) patients.,The FDA has gran...
Oncolytics Biotech® Highlights Key Developments and Future Studies in Cancer Treatments
October 04, 2024 05:57 AM PDT| By Team Kalkine MediaHighlights:,Oncolytics Biotech reports a median progression-free survival benefit of 5.7 months in the BRACELET-1 trial for HR+/HER2- breast cancer.,A Phase 2 study aimed at FDA accelerated approval is set to commence in the first half of 2025, focus...
_09_25_2024_14_24_01_892990.jpg)
Summit Therapeutics Completes Enrollment in HARMONi Trial for NSCLC Treatment
October 03, 2024 09:56 PM PDT| By Team Kalkine MediaKey Highlights,HARMONi Trial Enrollment: The trial successfully enrolled patients across North America, Europe, and China, marking a significant milestone in global clinical research.,FDA Fast Track Designation: The U.S. Food and Drug Administration...
.jpg)
Editas Medicine Secures $57 Million Through License Fee Sale
October 03, 2024 09:46 PM PDT| By Team Kalkine MediaHighlights,Editas has announced a financial transaction involving the sale of future license fees owed under its Cas9 license agreement with Vertex Pharmaceuticals.,Under the terms of the agreement, Editas Medicine is set to receive an upfront paymen...
Theriva Advances Clinical Trial with Positive Data
October 03, 2024 02:02 PM PDT| By Team Kalkine MediaHighlights,Theriva Biologics reported positive safety and pharmacokinetic data from the second cohort of its ongoing clinical trial for SYN-004, designed to prevent acute graft-versus-host disease in allogeneic hematopoietic cell transplant patients....
FDA Clears Key Hurdle for Eli Lilly's Blockbuster Drugs
October 03, 2024 01:18 PM PDT| By Team Kalkine MediaHighlights,The FDA has removed Eli Lilly’s popular weight-loss and diabetes drugs from its shortage list, reducing the market for compounded alternatives.,The removal follows efforts by Eli Lilly to increase supply, especially for Zepbound, as the co...
Navigating Change: Zimmer Biomet's Revised Analyst Ratings
October 03, 2024 12:38 PM PDT| By Team Kalkine MediaHeadlines,Zimmer Biomet experiences adjusted target prices from multiple research firms.,Analysts remain divided on the stock, reflecting various market perspectives.,Current consensus indicates cautious optimism for Zimmer Biomet's future performanc...
